![]() |
|||||||||||||||||
|
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|||||||||||
|
![]() |
EID
Home | Ahead of Print | Past
Issues | EID Search | Contact
Us | Announcements | Suggested
Citation
Volume 8, Number 5, May 2002 Perspective Evaluation in Nonhuman Primates of Vaccines against Ebola VirusThomas W. Geisbert,* Peter Pushko,* Kevin Anderson,* Jonathan Smith,*
Kelly J. Davis,* and Peter B. Jahrling* |
|
|
![]() |
|
Back to article | |
Figure. Sections of spleen from Ebola virus (EBOV)-infected animals. Top left, BALB/c mouse, note absence of polymerized fibrin (phosphotungstic acid [PTA] hematoxylin, original magnification X400). Field representative of five of five mice tested. Top right: guinea pig. Note discreet foci of polymerized fibrin (arrows) (PTA hematoxylin, original magnification X400). This field shows infrequent fibrin deposits; most fields in five of five animals examined showed no evidence of polymerized fibrin. Lower left: cynomolgus monkey. Note deposition of polymerized fibrin in red pulp (PTA hematoxylin, original magnification X400). Field representative of 25 of 25 monkeys. Lower right: cynomolgus monkey. Electron micrograph showing abundant fibrin deposits in red pulp (original magnification X5,300). Field representative of 11 of 11 monkeys examined. |
|
|
|
![]() |
EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z |
![]() |
![]() |
This page last reviewed June 21, 2002 |
![]() |
![]() |
Emerging
Infectious Diseases Journal |
![]() |